Salem Investment Counselors’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-200
Closed 952
2020
Q4
$0 Hold
200
﹤0.01% 850
2020
Q3
$0 Hold
200
﹤0.01% 750
2020
Q2
$1K Hold
200
﹤0.01% 690
2020
Q1
$1K Sell
200
-250
-56% -$824 ﹤0.01% 661
2019
Q4
$1K Buy
+450
New +$1.17K ﹤0.01% 684

Other funds holding BMY.RT

Salem Investment Counselors's BMY.RT Position: Q1 2021 in Review

Salem Investment Counselors sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 200 shares.

Salem Investment Counselors first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $1K in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Salem Investment Counselors reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Salem Investment Counselors sold 200 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021.
  • Salem Investment Counselors first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Salem Investment Counselors's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1K in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Salem Investment Counselors's 13F filing for Q1 2021, filed 17 May 2021.